What is Melanotan 1?
Melanotan-1 is associated with the NDP-alpha-MSH/afamelanotide peptide identity. The name alone does not establish equivalence to a particular pharmaceutical implant.
Mechanism & research focus
Afamelanotide activates melanocortin-1 receptors and promotes eumelanin production. Sequence and stereochemistry matter when connecting a research peptide to this literature.
What the research covers
SCENESSE studies evaluated a defined afamelanotide implant in adults with erythropoietic protoporphyria, including pain-free exposure to light.
What remains uncertain
Those findings concern a controlled implant formulation and a specific disease population. They do not establish the properties, safety or approval of a catalog vial or aerosol, or justify transferring implant outcomes to other formats.
The evidence label describes the linked research, not the suitability of a catalog product for use in people. Formulation, identity, purity, and measured content must be assessed separately.
Sources & studies
Afamelanotide: PubChem CID 16197727 ↗
Lists Melanotan-1 and NDP-alpha-MSH identity terminology.
SCENESSE afamelanotide implant: prescribing information ↗
Identity, mechanism and clinical context for the labeled formulation; not validation of a DA catalog product.
Read the full paper for its design, controls and limitations. A source link is not a claim that its tested material matches a DA formulation.
Catalog formats & documentation
Formats grouped by compound identity. Availability and batch documentation remain on Disguised Alpha.
Original DA reference: Melanotan 1 research guide ↗